Efficacy of Human Rotavirus Vaccine Against Rotavirus Gastroenteritis During the First 2 Years of Life in European Infants: Randomised, Double-Blind Controlled Study

This article, published in The Lancet, presents data that show high efficacy for GSK's Rotarix® administered with routine vaccines. Over two seasons, Rotarix® demonstrated 90 percent efficacy against severe rotavirus among European children and 79 percent against all rotavirus infections. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author(s): Vesikari T, Karvonen A, Prymula R, et al.

Published: 2007

  • Visit web page (English)

    (Located at www.ncbi.nlm.nih.gov)

    Citation: Vesikari T, Karvonen A, Prymula R, et al. Efficacy of Human Rotavirus Vaccine Against Rotavirus Gastroenteritis During the First 2 Years of Life in European Infants: Randomised, Double-blind Controlled Study. The Lancet. 2007;370(9601):1757-1763.

Resource types: Peer-reviewed journal

Diseases: Rotavirus

Topics: Vaccine safety; Disease/vaccine specific information

Regions: North America and Europe